Tasly Pharmaceutical Group's P134 cells represent a novel approach in the treatment of recurrent glioblastoma, targeting CD44 and CD133 antigens. Given the high unmet medical need in this indication, the asset has significant commercial potential. The market for glioblastoma therapies is competitive, with established treatments like temozolomide and emerging immunotherapies. Successful outcomes in this trial could position Tasly favorably against competitors, particularly if P134 demonstrates superior efficacy or safety profiles. Diligence is warranted to assess the scalability of manufacturing CAR-T cells and the regulatory pathway in various jurisdictions, particularly in light of evolving CAR-T therapy regulations.